INCATE supports innovators
to fight drug-resistant infections.
Our Work
Accelerating innovation against AMR
INCATE brings together translational and basic research, industry, experienced entrepreneurs, and investors to accelerate your innovation. We do this by providing advice, community, and funding. Our focus is on the development of new therapies and interventions that help reduce the prevalence and impact of Antimicrobial Resistance (AMR).
What we do
How we support your venture
Advice
Our partners provide advice on early alignment with medical needs and market demand, the development of a quality translational path, and entrepreneurship.
Community
Our community of industry professionals, academic experts, entrepreneurs, policymakers, investors, public health employees, and health care providers shares ideas and fights drug-resistant bacterial infections together.
Funding
Up to €250,000 in non-dilutive funding will be provided to selected projects to help answer critical questions needed to develop business and translational plans to convince investors at the next funding stage.
Our Vision
Bridge the gap!
What’s up?
Latest News
For the first time, INCATE’s Selection Committee didn’t simply meet — they came together in person at the headquarters of one of our industry partners, creating an atmosphere in Munich filled with energy, curiosity, and [...]
Obulytix has had an exciting start to the year, marked by important milestones and strengthening [...]
The 10th AMR Conference in Basel once again brought together some of the most passionate [...]
February 26, 2026— INCATE (INCubator for Antibacterial Therapies in Europe), the antimicrobial incubator supporting the [...]
The INCATE Selection Committee has selected five promising ventures to receive Stage I support. Want [...]
